Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 4Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Skin Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Squamous Cell 1Advanced Cancer 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Melanoma × tilsotolimod × Clear all
NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Idera Pharmaceuticals, Inc.

Phase 3 Terminated
481 enrolled 22 charts
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT02644967 2022-08-03

ILLUMINATE-204

Idera Pharmaceuticals, Inc.

Phase 2 Completed
53 enrolled 21 charts
Dermatologic

Melanoma

NCT04126876 2021-04-15

INTRIM

Amsterdam UMC, location VUmc

Phase 2 Recruiting
214 enrolled
Dermatologic

Melanoma

NCT03052205 2020-02-11

ILLUMINATE-101

Idera Pharmaceuticals, Inc.

Phase 1 Completed
54 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡